Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family

Bioorganic and Medicinal Chemistry

Volumn 25, Issue 9, 2017, Pages 2657-2665

  Bataille, Carole J R ^a   Brennan, Méabh B ^a   Byrne, Simon ^a   Davies, Stephen G ^a   Durbin, Matthew ^a   Fedorov, Oleg ^b   Huber, Kilian V M ^a   Jones, Alan M ^a   Knapp, Stefan ^b   Liu, Gu ^a   Nadali, Anna ^b   Quevedo, Camilo E ^a   Russell, Angela J ^a,b   Walker, Roderick G ^b   Westwood, Robert ^a   Wynne, Graham M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Anti cancer; High throughput screen; Kinase inhibitor; PIM kinase; Thiazolidine

Indexed keywords

ISOENZYME; PROTEIN SERINE THREONINE KINASE; THIAZOLIDINE DERIVATIVE; 5-((2-(3-N,N-DIMETHYLSULFAMOYLAMINO)THIAZOL-4-YL)METHYLENE)-2-THIOXOTHIAZOLIDIN-4-ONE; ANTINEOPLASTIC AGENT; ONCOPROTEIN; PIM1 PROTEIN, HUMAN; PIM2 PROTEIN, HUMAN; PIM3 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN KINASE PIM 1; RHODANINE; SULFONAMIDE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; K-562 CELL LINE; LEUKEMIA CELL LINE; MOLECULAR MODEL; MV4 11 CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; LIVER MICROSOME; MOLECULAR DOCKING; MOUSE; SOLUBILITY; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; ISOENZYMES; K562 CELLS; MICE; MICROSOMES, LIVER; MOLECULAR DOCKING SIMULATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-PIM-1; RHODANINE; SOLUBILITY; SULFONAMIDES; THIAZOLIDINES;

EID: 85015876936     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2017.02.056     Document Type: Article

References (74)

1. 1 Bononi, A., Agnoletto, C., De Marchi, E., et al. Protein kinases and phosphatases in the control of cell fate. Enzyme Res, 2011, 2011 329098-329098.
2. 2 Endicott, J.A., Noble, M.E.M., Johnson, L.N., The structural basis for control of eukaryotic protein kinases. Annu Rev Biochem Vol 81 (2012), 587–613 Edited by Kornberg RD, vol. 81.
3. 3 Manning, G., Whyte, D.B., Martinez, R., Hunter, T., Sudarsanam, S., The protein kinase complement of the human genome. Science (Washington, DC, U S) 298:5600 (2002), 1912–1916 1933–1934.
4. 4 McConnell, J.L., Wadzinski, B.E., Targeting protein serine/threonine phosphatases for drug development. Mol Pharmacol 75:6 (2009), 1249–1261.
5. 5 Cohen, P., Protein kinases – the major drug targets of the twenty-first century?. Nat Rev Drug Discov 1:4 (2002), 309–315.
6. 6 Blanco-Aparicio, C., Carnero, A., Pim kinases in cancer: diagnostic, prognostic and treatment opportunities. Biochem Pharmacol 85:5 (2013), 629–643.
7. 7 Cuypers, H.T., Selten, G., Quint, W., et al. Murine leukemia virus-induced T-cell lymphomagenesis – integration of proviruses in a distinct chromosomal region. Cell 37:1 (1984), 141–150.
8. 8 Merkel, A.L., Meggers, E., Ocker, M., PIM1 kinase as a target for cancer therapy. Expert Opin Investig Drugs 21:4 (2012), 425–436.
9. 9 Mikkers, H., Nawijn, M., Allen, J., et al. Mice deficient for All PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 24:13 (2004), 6104–6115.
10. 10 Nawijn, M.C., Alendar, A., Berns, A., For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 11:1 (2011), 23–34.
11. 11 Mizuno, K., Shirogane, T., Shinohara, A., Iwamatsu, A., Hibi, M., Hirano, T., Regulation of PIM1 by Hsp90. Biochem Biophys Res Commun 281:3 (2001), 663–669.
12. 12 Petersen Shay, K., Wang, Z., Xing, P.-X., McKenzie, I.F.C., Magnuson, N.S., PIM1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway. Mol Cancer Res 3:3 (2005), 170–181.
13. 13 Narlik-Grassow, M., Blanco-Aparicio, C., Cecilia, Y., et al. The essential role of PIM kinases in sarcoma growth and bone invasion. Carcinogenesis 33:8 (2012), 1479–1486.
14. 14 Beharry, Z., Mahajan, S., Zemskova, M., et al. The Pim protein kinases regulate energy metabolism and cell growth. Proc Natl Acad Sci USA 108:2 (2011), 528–533.
15. 15 Dar, A.C., Shokat, K.M., The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu Rev Biochem Vol. 80 (2011), 769–795 Edited by Kornberg RD, Raetz CRH, Rothman JE, Thorner JW, vol. 80.
16. 16 Ouhtit, A., Muzumdar, S., Gupta, I., Shanmuganathan, S., Tamimi, Y., Understanding the functional discrepancy of PIM1 in cancer. Front Biosci (Elite edition) 7 (2015), 208–214.
17. 17 Aguirre, E., Renner, O., Narlik-Grassow, M., Blanco-Aparicio, C., Genetic modeling of PIM proteins in cancer: proviral tagging and cooperation with oncogenes, tumor suppressor genes, and carcinogens. Front Oncol, 4, 2014 109-109.
18. 18 Narlik-Grassow, M., Blanco-Aparicio, C., Carnero, A., The PIM family of serine/threonine kinases in cancer. Med Res Rev 34:1 (2014), 136–159.
19. 19 Warfel, N.A., Kraft, A.S., PIM kinase (and Akt) biology and signaling in tumors. Pharmacol Ther 151 (2015), 41–49.
20. 20 Wang, J., Kim, J., Roh, M., et al. Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene 29:17 (2010), 2477–2487.
21. 21 Wang, M., Okamoto, M., Domenico, J., et al. Inhibition of Pim1 kinase prevents peanut allergy by enhancing Runx3 expression and suppressing T(H)2 and T(H)17 T-cell differentiation. J Allergy Clin Immunol, 130(4), 2012, 932.
22. 22 Maier, C.J., Maier, R.H., Rid, R., et al. PIM1 kinase interacts with the DNA binding domain of the vitamin D receptor: a further kinase implicated in signaling. Bmc Mol Biol, 2012, 13.
23. 23 Shin, Y.S., Takeda, K., Shiraishi, Y., et al. Inhibition of pim1 kinase activation attenuates allergen-induced airway hyperresponsiveness and inflammation. Am J Resp Cell Mol Biol 46:4 (2012), 488–497.
24. 24 Renard, S., Paulin, R., Breuils-Bonnet, S., et al. PIM1: A new biomarker in pulmonary arterial hypertension. Pulm Circ 3:1 (2013), 74–81.
25. 25 Jackson, L.J., Pheneger, J.A., Pheneger, T.J., et al. The role of PIM kinases in human and mouse CD4+ T cell activation and inflammatory bowel disease. Cell Immunol 272:2 (2012), 200–213.
26. 26 Borillo, G.A., Mason, M., Quijada, P., et al. PIM1 kinase protects mitochondrial integrity in cardiomyocytes. Circ Res 106:7 (2010), 1265–1274.
27. 27 Muraski, J.A., Rota, M., Misao, Y., et al. PIM1 regulates cardiomyocyte survival downstream of Akt. Nat Med 13:12 (2007), 1467–1475.
28. 28 Fischer, K.M., Cottage, C.T., Konstandin, M.H., Völkers, M., Khan, M., Sussman, M.A., PIM1 kinase inhibits pathological injury by promoting cardioprotective signaling. J Mol Cell Cardiol 51:4 (2011), 554–558.
29. 29 Xia, Z., Knaak, C., Ma, J., et al. Synthesis and evaluation of novel inhibitors of PIM1 and PIM2 protein kinases. J Med Chem 52:1 (2009), 74–86.
30. 30(a) Jacobs, M.D., Black, J., Futer, O., et al. PIM1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. J Biol Chem 280:14 (2005), 13728–13734.
31. 30(b) Bullock, A.N., Debreczeni, J., Amos, A.L., Knapp, S., Turk, B.E., Structure and substrate specificity of the Pim-1 kinase. J Biol Chem 280:50 (2005), 41675–41682.
32. 31 Qian, K.C., Wang, L., Hickey, E.R., et al. Structural basis of constitutive activity and a unique nucleotide binding mode of human PIM1 kinase. J Biol Chem 280:7 (2005), 6130–6137.
33. 32 Patricelli, M.P., Nomanbhoy, T.K., Wu, J., et al. In situ kinase profiling reveals functionally relevant properties of native kinases. Chem Biol 18:6 (2011), 699–710.
34. 33 Anastassiadis, T., Deacon, S.W., Devarajan, K., Ma, H., Peterson, J.R., Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 29:11 (2011), 1039–U1117.
35. 34 Brault, L., Gasser, C., Bracher, F., Huber, K., Knapp, S., Schwaller, J., PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 95:6 (2010), 1004–1015.
36. 35 Brault, L., Gasser, C., Bracher, F., Huber, K., Knapp, S., Schwaller, J., PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 95:6 (2010), 1004–1015.
37. 36 Eichmann, A., Yuan, L., Breant, C., Alitalo, K., Koskinen, P.J., Developmental expression of Pim kinases suggests functions also outside of the hematopoietic system. Oncogene 19:9 (2000), 1215–1224.
38. 37 Bullock, A.N., Debreczeni, J., Amos, A.L., Knapp, S., Turk, B.E., Structure and substrate specificity of the PIM1 kinase. J Biol Chem 280:50 (2005), 41675–41682.
39. 38 Mukaida, N., Wang, Y.Y., Li, Y.Y., Roles of PIM3, a novel survival kinase, in tumorigenesis. Cancer Sci 102:8 (2011), 1437–1442.
40. 39 Mikkers, H., Nawijn, M., Allen, J., et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 24:13 (2004), 6104–6115.
41. 40 Drygin, D., Haddach, M., Pierre, F., Ryckman, D.M., Potential use of selective and nonselective PIM kinase inhibitors for cancer therapy. J Med Chem 55:19 (2012), 8199–8208.
42. 41 Chen, L.S., Redkar, S., Taverna, P., Cortes, J.E., Gandhi, V., Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood 118:3 (2011), 693–702.
43. 42 Keeton E. AZD1208, a Novel, Potent and Selective Pan PIM Kinase Inhibitor, Demonstrates Efficacy in Models of Acute Myeloid Leukemia. In: 53rd ASH Annual Meeting; 2011.
44. 43 Dejan J. In: AACR 103rd Annual Meeting; 2012.
45. 44 Haddach, M., Michaux, J., Schwaebe, M.K., et al. Discovery of CX-6258. A potent, selective, and orally efficacious pan-Pim kinases inhibitor. Acs Med Chem Lett 3:2 (2012), 135–139.
46. 45 Lin, Y.-W., Beharry, Z.M., Hill, E.G., et al. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 115:4 (2010), 824–833.
47. 46 Natarajan, K., Bhullar, J., Shukla, S., et al. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by PIM1-dependent and -independent mechanisms. Biochem Pharmacol 85:4 (2013), 514–524.
48. 47 Kirschner, A.N., Wang, J., van der Meer, R., et al. PIM Kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. Jnci-J Natl Cancer Inst, 107(2), 2015.
49. 48 Burger, M.T., Han, W., Lan, J., et al. Structure guided optimization, in vitro activity, and in vivo activity of pan-PIM kinase inhibitors. Acs Med Chem Lett 4:12 (2013), 1193–1197.
50. 49 Keeton, E.K., McEachern, K., Dillman, K.S., et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood 123:6 (2014), 905–913.
51. 50 Raab, M.S., Ocio, E.M., Thomas, S.K., et al. Phase 1 study update of the novel Pan-Pim kinase inhibitor LGH447 in patients with relapsed/ refractory multiple myeloma. Blood, 124(21), 2014.
52. 51 Flanders, Y., Dumas, S., Caserta, J., et al. A versatile synthesis of novel pan-PIM kinase inhibitors with initial SAR study. Tetrahedron Lett 56:23 (2015), 3186–3190.
53. 52 Harada, M., Benito, J., Yamamoto, S., et al. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. Oncotarget 6:35 (2015), 37930–37947.
54. 53 Liu, Z., He, W., Gao, J., Luo, J., Huang, X., Gao, C., Computational prediction and experimental validation of a novel synthesized pan-PIM inhibitor PI003 and its apoptosis-inducing mechanisms in cervical cancer. Oncotarget 6:10 (2015), 8019–8035.
55. 54 Wang, H.-L., Cee, V.J., Chavez, F. Jr., et al. The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors. Bioorg Med Chem Lett 25:4 (2015), 834–840.
56. 55 <[ http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan>.
57. 56 Niesen, F.H., Berglund, H., Vedadi, M., The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc 2:9 (2007), 2212–2221.
58. 57 Kiianitsa, K., Solinger, J.A., Heyer, W.-D., NADH-coupled microplate photometric assay for kinetic studies of ATP-hydrolyzing enzymes with low and high specific activities. Anal Biochem 321:2 (2003), 266–271.
59. 58 Baell, J., Walters, M.A., Chemical con artists foil drug discovery. Nature 513:7519 (2014), 481–483.
60. 59 Erlanson, D.A., Learning from PAINful lessons. J Med Chem 58:5 (2015), 2088–2090.
61. 60(a) Mendgen, T., Steuer, C., Klein, C.D., Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry. J Med Chem 55:2 (2012), 743–753.
62. 60(b) Bhatti, R.S., Suresh, S.S., Krishan, P., Sandhu, J.S., Recent pharmacological developments on rhodanines and 2,4-thiazolidinediones. Int J Med Chem, 2013, 793260.
63. 61 Mendgen, T., Steuer, C., Klein, C.D., Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry. J Med Chem 55:2 (2012), 743–753.
64. 62 Knoevenagel, E., Condensation of malonic acid with aromatic aldehydes by ammonia and amines. Ber Dtsch chem Ges 31 (1898), 2596–2619.
65. 63 Pogacic, V., Bullock, A.N., Fedorov, O., et al. Structural analysis identifies imidazo 1,2-b Pyridazines as PIM kinase inhibitors with In vitro antileukemic activity. Cancer Res 67:14 (2007), 6916–6924.
66. 64 Kaminskyy, D., Khyluk, D., Vasylenko, O., Lesyk, R., An efficient method for the transformation of 5-ylidenerhodanines into 2,3,5-trisubstituted-4-thiazolidinones. Tetrahedron Lett 53:5 (2012), 557–559.
67. 65 Brem, J., van Berkel, S.S., Aik, W., et al. Rhodanine hydrolysis leads to potent thioenolate mediated metallo-beta-lactamase inhibition. Nat Chem 6:12 (2014), 1084–1090.
68. 66 Inamoto, K., Arai, Y., Hiroya, K., Doi, T., Palladium-catalysed direct synthesis of benzo b thiophenes from thioenols. Chem Commun 43 (2008), 5529–5531.
69. 67 Kandeel, K.A., The behaviour of E, Z-5-arylmethylidene-2-thioxo-1,3-thiazolidin-4-one and 3-[(2-oxo-2H-1-benzopyran-3-yl)dithio]-2H-1-benzopyran-2-one derivatives towards some amines. Chem Pap 58:5 (2004), 334–340.
70. 68 Russell, A.J., Westwood, I.M., Crawford, M.H.J., et al. Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse arylamine N-acetyltransferase 2. Bioorg Med Chem 17:2 (2009), 905–918.
71. 69 Huber, K., Brault, L., Fedorov, O., et al. 7,8-Dichloro-1-oxo-β-carbolines as a Versatile Scaffold for the Development of Potent and Selective Kinase Inhibitors with Unusual Binding Modes. J Med Chem 55:1 (2012), 403–413.
72. 70 Khurana, J.M., Sharma, V., A novel synthesis of 2-substituted 2H-imidazo[1,5-b]isoquinoline-1,5-diones by in situ desulfurization. Chem Heterocycl Compd (N Y, NY, US) 44:3 (2008), 309–313.
73. 71 Kim, K.-T., Levis, M., Small, D., Constitutively activated FLT3 phosphorylates BAD partially through PIM1. Br J Haematol 134:5 (2006), 500–509.
74. 72 Meeker, T.C., Loeb, J., Ayres, M., Sellers, W., The human PIM1 gene is selectively transcribed in different hemato-lymphoid cell lines in spite of a G+C-rich housekeeping promoter. Mol Cell Biol 10:4 (1990), 1680–1688.